STOCK TITAN
  1. Home
  2. Sec-filings
  3. PTCT
  4. [Form 4] PTC THERAPEUTICS, INC. Insider Trading Activity

PTCT EVP & CLO reports stock option exercise and share sales

Filing Impact
(Moderate)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

PTC Therapeutics executive reports option exercise and share sales

The Executive Vice President and Chief Legal Officer of PTC Therapeutics, Inc. (PTCT) reported transactions dated 11/17/2025. The officer exercised a stock option for 2,812 shares of common stock at an exercise price of $25.69 per share, then sold 1,843 shares at a weighted average price of $75.64, 777 shares at $76.53, and 192 shares at $77.18, all under a Rule 10b5-1 trading plan adopted on December 5, 2024.

After these transactions, the officer beneficially owned 103,901 shares of common stock directly and 25,314 stock options with an exercise price of $25.69 expiring on 02/14/2034. The reported option grant was made on February 15, 2024 and vests over four years, with 25% vesting on February 15, 2025 and 6.25% of the original grant vesting at the end of each three-month period thereafter.

Positive

  • None.

Negative

  • None.
Insider Boulding Mark Elliott
Role EXEC. VP AND CLO
Sold 2,812 shs ($214K)
Type Security Shares Price Value
Exercise Stock Option (Right to Buy) 2,812 $0.00 --
Exercise Common Stock 2,812 $25.69 $72K
Sale Common Stock 1,843 $75.64 $139K
Sale Common Stock 777 $76.53 $59K
Sale Common Stock 192 $77.18 $15K
Holdings After Transaction: Stock Option (Right to Buy) — 25,314 shares (Direct); Common Stock — 106,713 shares (Direct)
Footnotes (1)
  1. This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $75.06 to $76.04 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $76.08 to $77.07 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $77.10 to $77.33 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. This option was granted on February 15, 2024, and vests over four years, with 25% of the shares underlying the option vesting on February 15, 2025, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on May 15, 2025.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Boulding Mark Elliott
(Last) (First) (Middle)
C/O PTC THERAPEUTICS, INC.
500 WARREN CORPORATE CENTER DRIVE
(Street)
WARREN NJ 07059
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
PTC THERAPEUTICS, INC. [ PTCT ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
EXEC. VP AND CLO
3. Date of Earliest Transaction (Month/Day/Year)
11/17/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 11/17/2025 M(1) 2,812 A $25.69 106,713 D
Common Stock 11/17/2025 S(1) 1,843 D $75.64(2) 104,870 D
Common Stock 11/17/2025 S(1) 777 D $76.53(3) 104,093 D
Common Stock 11/17/2025 S(1) 192 D $77.18(4) 103,901 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $25.69 11/17/2025 M(1) 2,812 (5) 02/14/2034 Common Stock 2,812 $0 25,314 D
Explanation of Responses:
1. This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024.
2. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $75.06 to $76.04 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
3. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $76.08 to $77.07 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
4. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $77.10 to $77.33 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
5. This option was granted on February 15, 2024, and vests over four years, with 25% of the shares underlying the option vesting on February 15, 2025, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on May 15, 2025.
/s/ Avraham S. Adler, Attorney-in-Fact 11/19/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did PTCT report for its executive on this Form 4?

The Executive Vice President and Chief Legal Officer of PTC Therapeutics (PTCT) reported exercising a stock option for 2,812 shares of common stock on 11/17/2025 and selling those shares in several transactions on the same date.

At what prices did the PTCT executive sell common stock on 11/17/2025?

The officer sold 1,843 shares at a weighted average price of $75.64, 777 shares at $76.53, and 192 shares at $77.18, with each price representing weighted average sale prices from multiple trades within stated ranges.

How many PTCT shares does the reporting person own after the transactions?

Following the reported transactions, the officer beneficially owned 103,901 shares of PTCT common stock directly, as well as 25,314 stock options with an exercise price of $25.69 per share.

Was the PTCT insider trading under a Rule 10b5-1 plan?

Yes. The filing states that the transactions were effected under a written Rule 10b5-1 trading plan adopted by the reporting person on December 5, 2024.

What are the key terms of the PTCT executives stock option grant?

The stock option has an exercise price of $25.69 per share, covers 2,812 underlying shares reported in this transaction, and expires on 02/14/2034. It was granted on February 15, 2024 and vests over four years, with 25% vesting on February 15, 2025 and 6.25% of the original grant vesting at the end of each three-month period thereafter.

What is the reporting persons role and relationship to PTC Therapeutics (PTCT)?

The reporting person is an officer of PTC Therapeutics, Inc., serving as Executive Vice President and Chief Legal Officer, and files individually on this Form 4.